The impact of AI/data-driven drug discovery is evolving rapidly in life sciences.
Harnessing the beneficial potential of this technology, however, requires its optimal integration into R&D says Biorelate’s Dr Ben Sidders.
Data-driven, AI-enabled drug discovery is becoming a reality, reflected in the rise of ‘AI-first’ companies such as Recursion and Insilico Medicine. Traditional pharmaceutical companies are also embracing AI across their businesses.
Although previously the perceived value of AI in drug discovery and development has fallen short of the hype, a number of point solutions are now having a positive impact within aspects of R&D, providing pointers about how to successfully embed AI at its core.
Check out the rest of the feature here
